Related Experiment Video
Updated: Jun 22, 2026

Collection of Human Follicular Fluid, Follicle Somatic Cells, and Immature Oocytes from Individuals Undergoing In Vitro Fertilization
Published on: October 24, 2025
Effects of levetiracetam and valproate on reproductive endocrine function studied in human ovarian follicular cells
Erik Taubøll1, Ewa L Gregoraszczuk, Anna K Wojtowicz
1Department of Neurology, Division of Clinical Neurosciences, Rikshospitalet University Hospital, Oslo, Norway. erik.tauboll@rikshospitalet.no
Purpose:
Recent animal studies have indicated possible reproductive endocrine effects of levetiracetam (LEV). The aim of the present study was to investigate possible reproductive endocrine effects of LEV compared to valproate (VPA) using human ovarian follicular cells.
Methods:
Cell cultures of human granulosa cells were prepared. First, the effect of the drugs on basal and follicle-stimulating hormone (FSH)-stimulated estradiol secretion was investigated at different concentrations of LEV (12, 20, 50, or 80 microg/ml) or VPA (75, 100, 250, or 350 microg/ml). Second, the effect of the drugs on CYP19 aromatase activity was studied. Third, the possible effect of the drugs on cell apoptosis was investigated by measuring caspase-3 activity.
Results:
VPA significantly and concentration-dependently decreased basal and FSH-stimulated estradiol secretion. No effects on estradiol secretion were observed for LEV. Neither VPA nor LEV had any effect on CYP19 aromatase activity under basal conditions, but both drugs reduced CYP19 aromatase activity in FSH-stimulated cells at the higher concentrations (VPA 100, 250, and 350 microg/ml; LEV 20, 50, and 80 microg/ml). Both drugs significantly increased caspase-3 activity, the proapoptotic effect of LEV being more pronounced than VPA.
Discussion:
LEV acts differently from VPA on reproductive endocrine function when studied in human ovarian follicular cells. LEV does not affect estradiol secretion, although both drugs affect CYP19 aromatase activity after gonadotropin stimulation. Both drugs act as apoptotic agents in ovarian cells. The proapoptotic effect of LEV was more pronounced than that of VPA.
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Oogenesis
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Ovarian Cycle
Infertility in Females
Endometriosis, a condition characterized by abnormal growth of endometrial...

